Impacts of HIV infection and long-term use of antiretroviral therapy on the prevalence of oral human papilloma virus type 16

Journal of Oral Pathology and Medicine

Volumn 41, Issue 4, 2012, Pages 309-314

  Amornthatree, Korntip ^a   Sriplung, Hutcha ^a   Mitarnun, Winyou ^a   Nittayananta, Wipawee ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; HIV; Oncogenic virus; Oral human papilloma virus type 16; Saliva

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA EXTRACTION; DRUG EFFECT; FEMALE; GENE DOSAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; LONG TERM CARE; MALE; MOUTH HYGIENE; MOUTH INFECTION; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SALIVA ANALYSIS; TREATMENT DURATION; VIRUS CHARACTERIZATION; VIRUS ENVELOPE; VIRUS LOAD;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROTEASE INHIBITORS; PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; SALIVA; TRANSCRIPTION FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84858700306     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01117.x     Document Type: Article

References (28)

1. Campisi G, Panzarella V, Giuliani M, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions. Int J Oncol 2007; 30: 813-23.
2. Ha PK, Pai SI, Westra WH, et al. Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res 2002; 8: 1203-9.
3. McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck 1998; 20: 250-65.
4. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-20.
5. Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL. Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 1997; 123: 513-6.
6. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 1997; 79: 595-604.
7. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS 2009; 4: 52-6.
8. Kim RH, Yochim JM, Kang MK, Shin KH, Christensen R, Park NH. HIV-1 Tat enhances replicative potential of human oral keratinocytes harboring HPV-16 genome. Int J Oncol 2008; 33: 777-82.
9. Chuang AY, Chuang TC, Chang S, et al. Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol 2008; 44: 915-9.
10. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333: 450-1.
11. Charkraborty N, Bhattacharyya S, De C, et al. Incidence of multiple Herpesvirus infection in HIV seropositive patients, a big concern for Eastern Indian scenario. Virol J 2010; 7: 147.
12. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
13. Gillison ML. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009; 21: 439-44.
14. Cameron JE, Mercante D, O'Brien M, et al. The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. Sex Transm Dis 2005; 32: 703-9.
15. Syrjänen S. Human papillomavirus infection and its association with HIV. Adv Dent Res 2011; 23: 84-9.
16. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993; 22: 289-91.
17. Nittayananta W, Talungchit S, Jaruratanasirikul S, et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med 2010; 39: 397-406.
18. Tornesello ML, Buonaguro FM, Beth-Giraldo E, Giraldo G. Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression. Intervirology 1993; 36: 57-64.
19. Nyagol J, Leucci E, Onnis A, et al. The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther 2006; 5: 684-90.
20. Coutlee F, Trottier A-M, Ghattas G, et al. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis 1997; 24: 23-31.
21. Lawton G, Thomas S, Schonrock J, Monsour F, Frazer I. Human papillomaviruses in normal oral mucosa: a comparison of methods for sample collection. J Oral Pathol Med 1992; 21: 265-9.
22. Syrjänen KJ, Syrjänen SM. Papillomavirus infection in human pathology. London: Wiley, 2000.
23. Kellokoski JK, Syrjänen SM, Chang F, Yliskoski M, Syrjänen KJ. Southern blot hybridization and PCR in detection of oral human papillomavirus (HPV) infections in women with genital HPV infections. J Oral Pathol Med 1992; 21: 459-64.
24. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299-304.
25. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001; 357: 1411-2.
26. Danaher RJ, Wang C, Roland AT, Kaetzel CS, Greenberg RN, Miller CS. HIV protease inhibitors block oral epithelial cell DNA synthesis. Arch Oral Biol 2010; 55: 95-100.
27. Rintala M, Grénman S, Puranen M, Syrjänen S. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol 2006; 35: 89-94.
28. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-56.